

Gregor K Wenning

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1953491/publications.pdf>

Version: 2024-02-01

253
papers

20,068
citations

12330

69
h-index

12272

133
g-index

280
all docs

280
docs citations

280
times ranked

13937
citing authors

#	ARTICLE	IF	CITATIONS
1	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]-PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	3.9	18
2	Instrumented gait analysis defines the walking signature of CACNA1A disorders. <i>Journal of Neurology</i> , 2022, 269, 2941-2947.	3.6	5
3	The role of cardiovascular autonomic failure in the differential diagnosis of α -synucleinopathies. <i>Neurological Sciences</i> , 2022, 43, 187-198.	1.9	5
4	Multiple System Atrophy (MSA). , 2022, , 2409-2432.		0
5	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy. <i>Clinical Autonomic Research</i> , 2022, 32, 103-114.	2.5	7
6	Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis. <i>Movement Disorders</i> , 2022, 37, 1425-1431.	3.9	8
7	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	3.9	222
8	Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1369-1387.	2.8	10
9	Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders. <i>European Journal of Neurology</i> , 2022, 29, 2772-2780.	3.3	3
10	Disease Progression in Multiple System Atrophy—Novel Modeling Framework and Predictive Factors. <i>Movement Disorders</i> , 2022, 37, 1719-1727.	3.9	7
11	Bedside Assessment of Autonomic Dysfunction in Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2277-2281.	2.8	3
12	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 87-91.	2.2	16
13	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. <i>Movement Disorders</i> , 2021, 36, 449-459.	3.9	16
14	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 241-245.	3.9	15
15	Cardiovascular autonomic failure in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021, 1, 119-146.	0.1	0
16	Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. <i>Clinical Neurophysiology</i> , 2021, 132, 666-682.	1.5	88
17	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021, 31, 157-164.	2.5	22
18	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness. <i>Clinical Autonomic Research</i> , 2021, 31, 369-384.	2.5	48

#	ARTICLE	IF	CITATIONS
19	Emergent creativity in frontotemporal dementia. <i>Journal of Neural Transmission</i> , 2021, 128, 279-293.	2.8	14
20	Laboratory-supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the <scp>MoDiMSA Study Group</scp>. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 322-340.	1.5	7
21	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 30-36.	2.2	8
22	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 124-132.	2.2	22
23	Neuropathology of multiple system atrophy: Kurt Jellinger's legacy. <i>Journal of Neural Transmission</i> , 2021, 128, 1481-1494.	2.8	6
24	<scp>ATH434</scp> Reduces α -Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy. <i>Movement Disorders</i> , 2021, 36, 2605-2614.	3.9	11
25	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1052-1060.	1.5	6
26	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). <i>Autonomic Neuroscience: Basic and Clinical</i> , 2021, 233, 102792.	2.8	22
27	Kurt Jellinger, Doyen of international neuropathology. <i>Journal of Neural Transmission</i> , 2021, 128, 1479-1480.	2.8	0
28	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. <i>Movement Disorders</i> , 2021, 36, 2703-2705.	3.9	1
29	Current experimental disease-modifying therapeutics for multiple system atrophy. <i>Journal of Neural Transmission</i> , 2021, 128, 1529-1543.	2.8	11
30	Is Multiple System Atrophy a Prion-like Disorder?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10093.	4.1	12
31	Female sexual dysfunction in multiple system atrophy: a prospective cohort study. <i>Clinical Autonomic Research</i> , 2021, 31, 713-717.	2.5	10
32	Toll-like receptor 4 deficiency facilitates α -synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 59-65.	2.2	12
33	Autonomic failure: a neglected presentation of Parkinson's disease. <i>Lancet Neurology</i> , The, 2021, 20, 781-782.	10.2	6
34	Reliability and validity of Japanese version of Unified Multiple System Atrophy Rating Scale. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 171-180.	0.4	5
35	Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 1770-1779.	3.6	18
36	Gait and postural disorders in parkinsonism: a clinical approach. <i>Journal of Neurology</i> , 2020, 267, 3169-3176.	3.6	30

#	ARTICLE	IF	CITATIONS
37	Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome. <i>Journal of Sleep Research</i> , 2020, 29, e12875.	3.2	19
38	Parkinsonism and dysautonomia: Multiple system atrophy?. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 150-151.	2.2	1
39	Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020, 30, 7-8.	2.5	4
40	Cardiovascular autonomic testing in the work-up of cerebellar ataxia: insight from an observational single center study. <i>Journal of Neurology</i> , 2020, 267, 1097-1102.	3.6	5
41	Management of Orthostatic Hypotension in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, S57-S64.	2.8	34
42	Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. <i>Annals of Neurology</i> , 2020, 88, 712-722.	5.3	55
43	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.1	25
44	Commentary: Discriminating α -synuclein strains in parkinson's disease and multiple system atrophy. <i>Frontiers in Neuroscience</i> , 2020, 14, 802.	2.8	1
45	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.5	31
46	Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in α -Synucleinopathies. <i>Movement Disorders</i> , 2020, 35, 2333-2338.	3.9	8
47	Conjugal multiple system atrophy: Rethinking numbers of probability. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 176-177.	2.2	1
48	Cardiovascular autonomic function testing in multiple system atrophy and Parkinson's disease: an expert-based blinded evaluation. <i>Clinical Autonomic Research</i> , 2020, 30, 255-263.	2.5	10
49	Which Autonomic Features Distinguish Multiple System Atrophy and When. <i>Movement Disorders</i> , 2020, 35, 902-903.	3.9	0
50	Effects of self-administered cannabidiol in a patient with multiple system atrophy. <i>Clinical Autonomic Research</i> , 2020, 30, 355-356.	2.5	6
51	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. <i>Annals of Neurology</i> , 2020, 88, 643-645.	5.3	27
52	The footprint of orthostatic hypotension in parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 107-109.	2.2	3
53	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 57-63.	2.2	18
54	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 219-228.	3.7	31

#	ARTICLE	IF	CITATIONS
55	High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α -synucleinopathy. <i>Journal of Neuroinflammation</i> , 2020, 17, 35.	7.2	11
56	Olfaction in patients with isolated REM sleep behavior disorder who eventually develop multiple system atrophy. <i>Sleep</i> , 2020, 43, .	1.1	9
57	Which way does the axis tip? IBD increases the risk of Parkinson's disease. <i>Gut</i> , 2019, 68, 3-3.	12.1	3
58	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 23-27.	2.2	16
59	The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α -synuclein in experimental multiple system atrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 165513.	3.8	25
60	The Schellong test: detecting orthostatic blood pressure and heart rate changes in German-speaking countries. <i>Clinical Autonomic Research</i> , 2019, 29, 363-366.	2.5	24
61	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	10.2	79
62	Multiple system atrophy – Are cerebrospinal fluid cytokines reliable potential diagnostic marker?. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 1-2.	2.2	1
63	Urinary retention discriminates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1926-1928.	3.9	19
64	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 60-65.	2.2	23
65	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2019, 9, 681-691.	2.8	15
66	Stridor in multiple system atrophy. <i>Neurology</i> , 2019, 93, 630-639.	1.1	86
67	The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations. <i>Frontiers in Neurology</i> , 2019, 10, 5.	2.4	25
68	Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges. <i>Clinical Autonomic Research</i> , 2019, 29, 385-395.	2.5	2
69	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
70	TNF inhibitors as targets for protective therapies in MSA: a viewpoint. <i>Journal of Neuroinflammation</i> , 2019, 16, 80.	7.2	9
71	Iron in Neurodegeneration – Cause or Consequence?. <i>Frontiers in Neuroscience</i> , 2019, 13, 180.	2.8	204
72	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Movement Disorders</i> , 2019, 34, 1041-1048.	3.9	36

#	ARTICLE	IF	CITATIONS
73	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 301-309.	2.4	30
74	Early distinction of Parkinsonian variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 440-441.	3.9	21
75	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019, 149, 137-192.	2.0	74
76	Management of supine hypertension in patients with neurogenic orthostatic hypotension. <i>Journal of Hypertension</i> , 2019, 37, 1541-1546.	0.5	60
77	SYNE1-ataxia: Novel genotypic and phenotypic findings. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 210-214.	2.2	11
78	Anle138b modulates α -synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 255-263.	3.9	72
79	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 90-94.	2.2	49
80	The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1253-1273.	2.6	47
81	The reorganization of functional architecture in the early-stages of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 61-68.	2.2	64
82	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 81-87.	2.2	27
83	Autonomic function testing in spinocerebellar ataxia type 2. <i>Clinical Autonomic Research</i> , 2018, 28, 341-346.	2.5	13
84	Is multiple system atrophy an infectious disease?. <i>Annals of Neurology</i> , 2018, 83, 10-12.	5.3	16
85	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. <i>Acta Neuropathologica Communications</i> , 2018, 6, 2.	5.2	50
86	Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. <i>Sleep</i> , 2018, 41, .	1.1	38
87	Multiple system atrophy: experimental models and reality. <i>Acta Neuropathologica</i> , 2018, 135, 33-47.	7.7	20
88	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.1	23
89	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 47-55.	2.2	45
90	Region-Specific Effects of Immunotherapy With Antibodies Targeting α -synuclein in a Transgenic Model of Synucleinopathy. <i>Frontiers in Neuroscience</i> , 2018, 12, 452.	2.8	31

#	ARTICLE	IF	CITATIONS
91	Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS). <i>Clinical Autonomic Research</i> , 2018, 28, 355-362.	2.5	176
92	Autonomic function testing in Friedreichâ€™s ataxia. <i>Journal of Neurology</i> , 2018, 265, 2015-2022.	3.6	14
93	Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived Î±-synuclein in oligodendroglia: implications for MSA pathogenesis. <i>BMC Neuroscience</i> , 2018, 19, 32.	1.9	11
94	Sensorâ€based gait analysis in atypical parkinsonian disorders. <i>Brain and Behavior</i> , 2018, 8, e00977.	2.2	43
95	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	2.2	17
96	Very lateâ€onset pure autonomic failure. <i>Movement Disorders</i> , 2017, 32, 1106-1108.	3.9	4
97	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
98	Multiple system atrophy: insights into a rare and debilitating movement disorder. <i>Nature Reviews Neurology</i> , 2017, 13, 232-243.	10.1	128
99	Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. <i>Journal of Neural Transmission</i> , 2017, 124, 1567-1605.	2.8	74
100	Cognitive impairment in multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 1338-1339.	3.9	19
101	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. <i>Movement Disorders</i> , 2017, 32, 1356-1364.	3.9	11
102	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017, 124, 293-302.	2.8	46
103	Distinct Parameters in the EEG of the PLP Î±-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 10, 252.	2.0	14
104	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0189897.	2.5	44
105	Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal Î±-synucleinopathy. <i>Molecular Neurodegeneration</i> , 2017, 12, 52.	10.8	73
106	Autonomic History Taking and Key Symptoms: Where Is the Autonomic Disease?. , 2017, , 15-36.		1
107	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. <i>Frontiers in Neuroscience</i> , 2016, 10, 99.	2.8	23
108	Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. <i>PLoS ONE</i> , 2016, 11, e0150705.	2.5	26

#	ARTICLE	IF	CITATIONS
109	Preface. Movement Disorders, 2016, 31, 151-151.	3.9	0
110	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. Movement Disorders, 2016, 31, 235-240.	3.9	9
111	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. Movement Disorders, 2016, 31, 1577-1581.	3.9	14
112	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology, 2016, 86, 1242-1249.	1.1	89
113	Multiple system atrophy: pathogenic mechanisms and biomarkers. Journal of Neural Transmission, 2016, 123, 555-572.	2.8	55
114	Overlaps between multiple system atrophy and multiple sclerosis: A novel perspective. Movement Disorders, 2016, 31, 1767-1771.	3.9	5
115	Is Multiple System Atrophy a New Prion Disorder?. Movement Disorders, 2016, 31, 300-300.	3.9	2
116	Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. Neurotherapeutics, 2016, 13, 871-879.	4.4	17
117	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
118	Supine hypertension in Parkinson's disease and multiple system atrophy. Clinical Autonomic Research, 2016, 26, 97-105.	2.5	87
119	Clia and alpha-synuclein in neurodegeneration: A complex interaction. Neurobiology of Disease, 2016, 85, 262-274.	4.4	156
120	Overexpression of α -synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. BMC Neuroscience, 2015, 16, 86.	1.9	5
121	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Movement Disorders, 2015, 30, 1068-1076.	3.9	125
122	Involvement of Peripheral Nerves in the Transgenic PLP- α -Syn Model of Multiple System Atrophy: Extending the Phenotype. PLoS ONE, 2015, 10, e0136575.	2.5	17
123	Multiple-System Atrophy. New England Journal of Medicine, 2015, 372, 1374-1376.	27.0	53
124	Multiple-System Atrophy. New England Journal of Medicine, 2015, 372, 249-263.	27.0	600
125	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurology, The, 2015, 14, 145-152.	10.2	90
126	Animal models of multiple system atrophy. Clinical Autonomic Research, 2015, 25, 9-17.	2.5	55

#	ARTICLE	IF	CITATIONS
127	Multiple system atrophy in the USA: another piece in the jigsaw. <i>Lancet Neurology</i> , The, 2015, 14, 672-674.	10.2	0
128	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. <i>Nature Communications</i> , 2015, 6, 7247.	12.8	170
129	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. <i>Neurobiology of Disease</i> , 2015, 80, 29-41.	4.4	71
130	Enteric nervous system α -synuclein immunoreactivity in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2015, 85, 1761-1768.	1.1	121
131	Sex and age effects on cardiovascular autonomic function in healthy adults. <i>Clinical Autonomic Research</i> , 2015, 25, 317-326.	2.5	24
132	Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. <i>Neurotoxicity Research</i> , 2015, 28, 185-194.	2.7	38
133	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1393-1397.	2.2	33
134	Animal Models of Multiple-System Atrophy. , 2015, , 887-904.		0
135	Cognition in a multiple system atrophy series of cases from Argentina. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 773-776.	0.8	11
136	An update on the cerebellar subtype of multiple system atrophy. <i>Cerebellum and Ataxias</i> , 2014, 1, 14.	1.9	16
137	Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology</i> , 2014, 118, 19-35.	5.7	35
138	Rifampicin for multiple system atrophy. <i>Lancet Neurology</i> , The, 2014, 13, 237-239.	10.2	3
139	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	3.9	193
140	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. <i>Journal of Neurology</i> , 2014, 261, 1291-1299.	3.6	47
141	Autonomic failure in CANVAS syndrome. <i>Brain</i> , 2014, 137, 2625-2626.	7.6	4
142	Multiple system atrophy as emerging template for accelerated drug discovery in α -synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 793-799.	2.2	18
143	Do periodic arm movements during sleep exist in healthy subjects? A polysomnographic study. <i>Sleep Medicine</i> , 2014, 15, 1150-1154.	1.6	7
144	Clinical Presentation. , 2014, , 97-119.		0

#	ARTICLE	IF	CITATIONS
145	Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. <i>Journal of Neurology</i> , 2013, 260, 2212-2219.	3.6	106
146	Multiple system atrophy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 229-241.	1.8	31
147	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 264-274.	10.2	426
148	Multiple System Atrophy (MSA). , 2013, , 2119-2141.		0
149	Toll-like receptor 4 is required for α -synuclein dependent activation of microglia and astroglia. <i>Glia</i> , 2013, 61, 349-360.	4.9	542
150	Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence. <i>Experimental Neurology</i> , 2013, 247, 531-536.	4.1	46
151	Models of Multiple System Atrophy. <i>Current Topics in Behavioral Neurosciences</i> , 2013, 22, 369-393.	1.7	16
152	Bladder dysfunction in a transgenic mouse model of multiple system atrophy. <i>Movement Disorders</i> , 2013, 28, 347-355.	3.9	50
153	Intact Olfaction in a Mouse Model of Multiple System Atrophy. <i>PLoS ONE</i> , 2013, 8, e64625.	2.5	20
154	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. <i>Movement Disorders</i> , 2012, 27, 1683-1685.	3.9	18
155	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. <i>Proteome Science</i> , 2012, 10, 71.	1.7	22
156	Behavioral and histological analysis of a partial double lesion model of parkinsonian variant multiple system atrophy. <i>Journal of Neuroscience Research</i> , 2012, 90, 1284-1295.	2.9	10
157	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123 I] 2 -CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1012-1020.	6.4	40
158	Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α -synuclein under oligodendrocyte promoter: implications for multiple system atrophy. <i>Acta Neuropathologica</i> , 2012, 124, 51-65.	7.7	73
159	Premotor signs and symptoms of multiple system atrophy. <i>Lancet Neurology</i> , The, 2012, 11, 361-368.	10.2	201
160	Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model. <i>Neurotoxicity Research</i> , 2012, 21, 393-404.	2.7	96
161	Toll-Like Receptor 4 Promotes α -Synuclein Clearance and Survival of Nigral Dopaminergic Neurons. <i>American Journal of Pathology</i> , 2011, 179, 954-963.	3.8	230
162	Genetic players in multiple system atrophy: unfolding the nature of the beast. <i>Neurobiology of Aging</i> , 2011, 32, 1924.e5-1924.e14.	3.1	39

#	ARTICLE	IF	CITATIONS
163	The differential diagnosis of parkinsonism: A clinical approach. , 2011, , 126-141.		0
164	New insights into atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2011, 24, 331-338.	3.6	27
165	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). <i>Archives of Neurology</i> , 2011, 68, 223-30.	4.5	83
166	Glial dysfunction in the pathogenesis of α -synucleinopathies: emerging concepts. <i>Acta Neuropathologica</i> , 2011, 121, 675-693.	7.7	164
167	Modelling progressive autonomic failure in MSA: where are we now?. <i>Journal of Neural Transmission</i> , 2011, 118, 841-847.	2.8	2
168	A novel computer-assisted image analysis of [123I] β -CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 702-710.	6.4	27
169	Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. <i>Movement Disorders</i> , 2011, 26, 507-515.	3.9	17
170	Milestones in atypical and secondary Parkinsonisms. <i>Movement Disorders</i> , 2011, 26, 1083-1095.	3.9	74
171	Mesenchymal Stem Cells in a Transgenic Mouse Model of Multiple System Atrophy: Immunomodulation and Neuroprotection. <i>PLoS ONE</i> , 2011, 6, e19808.	2.5	77
172	Combination Lesion Models of MSA. <i>Neuromethods</i> , 2011, , 37-54.	0.3	0
173	Minocycline 1-year therapy in multiple system atrophy: Effect on clinical symptoms and [¹¹ C]-(R)-PK11195 PET (MEMSA-trial). <i>Movement Disorders</i> , 2010, 25, 97-107.	3.9	163
174	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	3.9	205
175	Etiology, Pathology, and Pathogenesis. <i>Blue Books of Neurology</i> , 2010, 34, 321-339.	0.1	2
176	Multiple system atrophy masking multiple sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2010, 112, 59-61.	1.4	7
177	Targeted overexpression of human α -synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. <i>Experimental Neurology</i> , 2010, 224, 459-464.	4.1	65
178	SNCA variants are associated with increased risk for multiple system atrophy. <i>Annals of Neurology</i> , 2009, 65, 610-614.	5.3	257
179	Striatal transplantation in a rodent model of multiple system atrophy: Effects on Dopa response. <i>Journal of Neuroscience Research</i> , 2009, 87, 1679-1685.	2.9	23
180	Mitochondrial inhibitor 3-nitropropionic acid enhances oxidative modification of α -synuclein in a transgenic mouse model of multiple system atrophy. <i>Journal of Neuroscience Research</i> , 2009, 87, 2728-2739.	2.9	78

#	ARTICLE	IF	CITATIONS
181	Assessing disease progression with MRI in atypical parkinsonian disorders. <i>Movement Disorders</i> , 2009, 24, S699-702.	3.9	17
182	Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2. <i>Movement Disorders</i> , 2009, 24, 1407-1409.	3.9	8
183	A validation exercise on the new consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2009, 24, 2272-2276.	3.9	100
184	Recent developments in multiple system atrophy. <i>Journal of Neurology</i> , 2009, 256, 1791-1808.	3.6	86
185	Striatal transplantation for multiple system atrophy – Are grafts affected by α -synucleinopathy?. <i>Experimental Neurology</i> , 2009, 219, 368-371.	4.1	28
186	No need to droop your head in Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 620.	2.2	0
187	Prospective Differentiation of Multiple System Atrophy From Parkinson Disease, With and Without Autonomic Failure. <i>Archives of Neurology</i> , 2009, 66, 742-50.	4.5	133
188	Survival in multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 294-296.	3.9	112
189	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 1093-1099.	3.9	215
190	Multiple system atrophy: A primary oligodendroglialopathy. <i>Annals of Neurology</i> , 2008, 64, 239-246.	5.3	279
191	Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. <i>Experimental Neurology</i> , 2008, 210, 421-427.	4.1	79
192	Parkinson-Plus Disorders. , 2008, , 157-175.		1
193	Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2007, 22, 353-358.	3.9	13
194	Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2007, 22, 1138-1144.	3.9	66
195	Diffusion weighted imaging best discriminates PD from MSA: A comparison with tilt table testing and heart MIBG scintigraphy. <i>Movement Disorders</i> , 2007, 22, 1771-1776.	3.9	92
196	Disproportionate antecollis: A warning sign for multiple system atrophy. <i>Movement Disorders</i> , 2007, 22, 1986-1986.	3.9	5
197	Microglial activation mediates neurodegeneration related to oligodendroglial α -synucleinopathy: Implications for multiple system atrophy. <i>Movement Disorders</i> , 2007, 22, 2196-2203.	3.9	203
198	Progression of brain atrophy in multiple system atrophy. <i>Journal of Neurology</i> , 2007, 254, 191-196.	3.6	108

#	ARTICLE	IF	CITATIONS
199	Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study. <i>NeuroImage</i> , 2006, 31, 240-245.	4.2	98
200	The diagnosis of multiple system atrophy. <i>Journal of Neurology</i> , 2006, 253, iii2-iii15.	3.6	6
201	The diagnosis of Parkinson's disease. <i>Lancet Neurology</i> , The, 2006, 5, 75-86.	10.2	665
202	Cortical atrophy in the cerebellar variant of multiple system atrophy: A voxelâ€based morphometry study. <i>Movement Disorders</i> , 2006, 21, 159-165.	3.9	67
203	Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). <i>Movement Disorders</i> , 2006, 21, 179-186.	3.9	126
204	Healthâ€related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 809-815.	3.9	102
205	Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study. <i>Movement Disorders</i> , 2006, 21, 847-852.	3.9	62
206	Olivopontocerebellar atrophy: Toward a better nosological definition. <i>Movement Disorders</i> , 2006, 21, 1607-1613.	3.9	48
207	The role of α -synuclein and tau in neurodegenerative movement disorders. <i>Current Opinion in Neurology</i> , 2005, 18, 357-362.	3.6	40
208	Placebo-Controlled Trial of Amantadine in Multiple-System Atrophy. <i>Clinical Neuropharmacology</i> , 2005, 28, 225-227.	0.7	44
209	Animal models of multiple system atrophy. <i>Trends in Neurosciences</i> , 2005, 28, 501-506.	8.6	77
210	How to diagnose dementia with Lewy bodies: State of the art. <i>Movement Disorders</i> , 2005, 20, S11-S20.	3.9	304
211	Grading of neuropathology in multiple system atrophy: Proposal for a novel scale. <i>Movement Disorders</i> , 2005, 20, S29-S36.	3.9	161
212	In vitro models of multiple system atrophy. <i>Movement Disorders</i> , 2005, 20, S53-S56.	3.9	22
213	Therapeutic strategies in multiple system atrophy. <i>Movement Disorders</i> , 2005, 20, S67-S76.	3.9	42
214	The role of β -synuclein in the pathogenesis of multiple system atrophy. <i>Acta Neuropathologica</i> , 2005, 109, 129-140.	7.7	97
215	Progression of parkinsonism in multiple system atrophy. <i>Journal of Neurology</i> , 2005, 252, 91-96.	3.6	55
216	Multiple system atrophy. , 2005, , 623-662.		2

#	ARTICLE	IF	CITATIONS
217	Voxel-wise analysis of [¹²³ I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain</i> , 2005, 128, 1605-1612.	7.6	115
218	Oxidative Stress in Transgenic Mice with Oligodendroglial α-Synuclein Overexpression Replicates the Characteristic Neuropathology of Multiple System Atrophy. <i>American Journal of Pathology</i> , 2005, 166, 869-876.	3.8	191
219	Multiple system atrophy. <i>Lancet Neurology</i> , The, 2004, 3, 93-103.	10.2	443
220	Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. <i>Journal of Neuroscience Research</i> , 2004, 78, 87-91.	2.9	28
221	Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1020-1028.	3.9	1,739
222	Comparison of diffusion-weighted imaging and [¹²³ I]β-CIT SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1438-1445.	3.9	86
223	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Movement Disorders</i> , 2004, 19, 1391-1402.	3.9	481
224	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>NeuroImage</i> , 2004, 21, 1443-1451.	4.2	149
225	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. <i>NeuroReport</i> , 2004, 15, 1711-1714.	1.2	40
226	Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system) <i>Trends Neurosci</i> 2004, 27, 377-384.	10.1	377
227	Tumor necrosis factor-α-induced cell death in U373 cells overexpressing α-synuclein. <i>Journal of Neuroscience Research</i> , 2003, 73, 334-340.	2.9	37
228	Increased daytime sleepiness in Parkinson's disease: A questionnaire survey. <i>Movement Disorders</i> , 2003, 18, 319-323.	3.9	70
229	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2003, 18, 1132-1138.	3.9	153
230	Multiple system atrophy: An update. <i>Movement Disorders</i> , 2003, 18, 34-42.	3.9	71
231	Freezing of gait in postmortem-confirmed atypical parkinsonism. <i>Movement Disorders</i> , 2002, 17, 1041-1045.	3.9	46
232	Simultaneous Intrastratial 6-Hydroxydopamine and Quinolinic Acid Injection: A Model of Early-Stage Striatonigral Degeneration. <i>Experimental Neurology</i> , 2001, 167, 133-147.	4.1	51
233	Is peripheral neuropathy a feature of multiple system atrophy?. <i>Clinical Autonomic Research</i> , 2001, 11, 63-63.	2.5	1
234	Glial cell death induced by overexpression of α-synuclein. <i>Journal of Neuroscience Research</i> , 2001, 65, 432-438.	2.9	87

#	ARTICLE	IF	CITATIONS
235	Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders. Archives of Neurology, 2001, 58, 259.	4.5	375
236	An early report of striatonigral degeneration. Movement Disorders, 2000, 15, 159-162.	3.9	7
237	Cortical and brain stem hyperexcitability in a pathologically confirmed case of multiple system atrophy. Movement Disorders, 2000, 15, 362-363.	3.9	17
238	Toward a primate model of l-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. Movement Disorders, 2000, 15, 531-536.	3.9	43
239	Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using 123I- β -CIT and 123I-IBZM. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1410-1414.	2.1	125
240	Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy). Experimental Neurology, 2000, 164, 166-175.	4.1	16
241	Progression of falls in postmortem-confirmed Parkinsonian disorders. Movement Disorders, 1999, 14, 947-950.	3.9	144
242	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. Neuroscience Letters, 1999, 274, 61-65.	2.1	26
243	123I- β -CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Movement Disorders, 1998, 13, 438-445.	3.9	48
244	Consensus statement on the diagnosis of multiple system atrophy. Clinical Autonomic Research, 1998, 8, 359-362.	2.5	823
245	Brain perfusion scintigraphy with ^{99m}Tc -HMPAO or ^{99m}Tc -ECD and 123I- β -CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 320-325.	2.1	137
246	The "cold hands sign" in multiple system atrophy. Movement Disorders, 1997, 12, 514-518.	3.9	58
247	Corticobasal degeneration. , 0, , 75-98.		1
248	Multiple system atrophy. , 0, , 1-15.		0
249	Parkinsonism "other causes. , 0, , 99-125.		1
250	Magnetic resonance imaging of multiple system atrophy. , 0, , 167-203.		0
251	Parkinson's disease and the spectrum of Lewy body disease. , 0, , 10-26.		0
252	Multiple system atrophy. , 0, , 27-57.		0

#	ARTICLE	IF	CITATIONS
253	Non-pharmacological treatment for atypical parkinsonism. , 0, , 142-159.		0